GSK and Roche Korea jointly to launch once-a-month anti-osteoporosis drug.

Roche Korea and GSK took the KFDA approval of "Bonviva 150mg tab" (ibandronate), just administering once a month, which is the first dosage form of once a month administration in Korea for the treatment of the post menopause osteoporosis. It may be launched into the local market during the 1/4 of next year.

The two companies said that ibandronate showed an excellent efficacy and tolerance b...